CD8A and neoplasm: IL-35 inhibits the function of Th1 and Th17 cells while increasing the regulatory function of CD4+ T cells and reducing the cytolytic activity of CD8+ T cells, highlighting its role in the induction of T cell exhaustion and dysfunction, favoring tumor progression (Wang et al., 2018).